Related articles

Artesunate, a derivative of artemisinin extracted from the plant Artemisia annua, is traditionally known for its anti-malarial properties. However, recent studies suggest that IV artesunate possesses potential anti-cancer effects. Used as an adjunct therapy in integrative oncology, it has gained interest due to its selective toxicity against cancer cells. This article explores the scientific mechanisms, clinical evidence, and therapeutic potential of IV artesunate for cancer patients.

Glutathione is a powerful antioxidant found in every cell of the body, playing a crucial role in detoxification, immune function, and cellular protection. Intravenous (IV) glutathione therapy has gained attention in integrative oncology due to its potential anti-cancer properties, protection against chemotherapy toxicity, and support for overall well-being. This article explores the scientific mechanisms, clinical evidence, and benefits of IV glutathione therapy for cancer patients.

Alpha-Lipoic Acid (ALA) is a naturally occurring antioxidant and metabolic cofactor that plays a critical role in energy production, oxidative stress reduction, and mitochondrial function. Intravenous (IV) ALA therapy has gained attention in integrative oncology due to its potential anti-cancer effects, neuroprotective properties, and ability to reduce chemotherapy-induced side effects. This article explores the scientific mechanisms, clinical evidence, and therapeutic benefits of IV ALA therapy in cancer care.

Albumin is a crucial protein in the blood that plays a vital role in maintaining oncotic pressure, transporting nutrients, and supporting immune function. Intravenous (IV) albumin therapy is often used in cancer patients who experience hypoalbuminemia (low albumin levels) due to malnutrition, chronic inflammation, or cancer-related cachexia. This article explores the scientific mechanisms, clinical evidence, and therapeutic benefits of IV albumin therapy in cancer care.

In the realm of integrative oncology, intravenous (IV) high-dose vitamin C (HDIVC) has gained attention as a complementary treatment for cancer patients. Unlike oral vitamin C, which has limited absorption due to gastrointestinal regulation, IV administration allows for significantly higher plasma concentrations, potentially exerting pro-oxidant effects against cancer cells. But what does the science say? This article delves into the scientific rationale, clinical evidence, and potential benefits of HDIVC for cancer patients.